<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03807856</url>
  </required_header>
  <id_info>
    <org_study_id>18-004345</org_study_id>
    <nct_id>NCT03807856</nct_id>
  </id_info>
  <brief_title>Treating Acute Pancreatitis With Dabigatran, a Pilot Study</brief_title>
  <official_title>Treating Acute Pancreatitis With Dabigatran, a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Researchers are studying the safety and efficacy of Dabigatran in the treatment of acute
      pancreatitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with acute pancreatitis who meet the inclusion and exclusion criteria for the study
      will be recruited. Subjects will be randomized to receive either Dabigatran 150mg daily for
      three days or standard treatment. Vital signs, CBC, inflammatory markers and BMP, and
      bleeding complications will be evaluated daily for the next 7 days of until discharge
      whichever is sooner.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 24, 2019</start_date>
  <completion_date type="Anticipated">August 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>One year</time_frame>
    <description>Number of Reported Adverse Events</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Acute Pancreatitis</condition>
  <arm_group>
    <arm_group_label>Dabigatran Etexilate Mesylate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dabigatran 150mg BID for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard treatment for acute pancreatitis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran Etexilate Mesylate</intervention_name>
    <description>Dabigatran 150mg BID for 3 days</description>
    <arm_group_label>Dabigatran Etexilate Mesylate</arm_group_label>
    <other_name>Pradaxa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Daily vital signs, lab work and one outpatient clinic visit</description>
    <arm_group_label>Dabigatran Etexilate Mesylate</arm_group_label>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute Pancreatitis (presence at least two of three features: typical pain, amylase or
             lipase &gt;3 times UNL and AP on images)

          -  18-75 years old

          -  Willingness to sign the informed consent

          -  Symptom onset within 72 hours

        Exclusion Criteria:

          -  Under 18 years of age or over 75 years of age

          -  Pregnancy or lactating

          -  Presence of pseudo aneurysm on CT

          -  Predicted severe acute pancreatitis

          -  Unwilling or unable to sign the informed consent

          -  Had recent surgery or sphincterotomy

          -  Active pathological bleeding

          -  Concurrent use of anti-coagulation

          -  Known serious hypersensitivity reaction to Dabigatran

          -  CrCI &lt;30mL/min or on dialysis

          -  Mechanical prosthetic valves

          -  Liver disease

          -  Cancer

          -  On Chemotherapy or immunosuppressant

          -  Persistent ALT, AST, Akl Phos &gt;2 x ULN

          -  Active hepatitis C, active hepatitis B, and active hepatitis A

          -  Anemia (hemoglobin &lt;10g/dL)

          -  Thrombocytopenia

          -  Concomitant use of P-gp inhibitors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yan Bi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yan Bi, MD</last_name>
    <phone>9049536970</phone>
    <email>bi.yan@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Bi</last_name>
      <phone>904-953-6970</phone>
      <email>bi.yan@mayo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 15, 2019</study_first_submitted>
  <study_first_submitted_qc>January 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2019</study_first_posted>
  <last_update_submitted>May 20, 2020</last_update_submitted>
  <last_update_submitted_qc>May 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Yan Bi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

